Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597894 | 0.88 | SIRT2 (0.37) | SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL21597895 | 0.88 | SIRT2 (0.37) | SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL16424839 | 0.87 | CA1 (0.52) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL16862492 | 0.84 | CA1 (0.50) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL19776121 | 0.84 | CA1 (0.50) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL31726507 | 0.84 | CA1 (0.50) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL16847607 | 0.84 | MAPT (0.49) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL21450347 | 0.84 | CA2 (0.49) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL31121268 | 0.82 | CA1 (0.44) | CA1CA2MAPTTDP1KDM4E | |
| SCHEMBL14950097 | 0.82 | SIRT5 (0.42) | CA1CA2MAPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344261-B2 | Immunomodulatory conjugates | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2019-07-09 | — | — | US | disclosed |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | Ascend Biopharamaceuticals Ltd (AU) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344261-B2 | Immunomodulatory conjugates | CLEC4M, TLR3, CD74 | CA1 3928/4885CA2 4208/4885MAPT 2147/4885 |
| US-20150030626-A1 | IMMUNOMODULATORY CONJUGATES | CLEC4M, TLR3, CD74 | CA1 3928/4885CA2 4208/4885MAPT 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.